German Supreme Court Grants Lilly Appeal in Alimta(R) Vitamin Regimen Patent Lawsuit
Alimta Case Returned to Court of Appeal for New Ruling
INDIANAPOLIS, June 14, 2016 -- (Healthcare Sales & Marketing Network) -- The German Federal Supreme Court has granted the appeal by Eli Lilly and Company (LLY) in the case of Eli Lilly and Company ... Biopharmaceuticals, Generics, LitigationEli Lilly, Actavis, Alimta , pemetrexed (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2016 Category: Pharmaceuticals Source Type: news
Canadian Doctors Test Pemetrexed in Mesothelioma HIPEC Treatment,...
Researchers say the mesothelioma drug has potential for use in heated chemotherapy technique.(PRWeb June 04, 2016)Read the full story at http://www.prweb.com/releases/2016/06/prweb13461333.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 4, 2016 Category: Pharmaceuticals Source Type: news
Alimta (Pemetrexed) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 19, 2016 Category: Drugs & Pharmacology Source Type: news
Immunotherapy Vaccine for Mesothelioma Gets High Marks
Immunotherapy vaccine CRS-207 is moving closer to changing the way malignant pleural mesothelioma will be treated in the future.
CRS-207 produced a startling 94 percent disease control rate when combined with a chemotherapy cocktail of cisplatin and pemetrexed in a recent, multicenter clinical trial.
Thoracic oncologist Dr. Thierry Jahan of the UCSF Helen Diller Family Comprehensive Cancer Center detailed the results last week at the 2016 European Lung Cancer Conference.
“We’ve seen a really impressive response,” Jahan said. “It’s an impressive signal for a study like this.”
The CRS-207 vaccine is a...
Source: Asbestos and Mesothelioma News - May 3, 2016 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news
New Case Report Illustrates Power of “Maintenance Therapy” for...
Chinese researchers say administering a maintenance dose of the mesothelioma drug pemetrexed produced a “perfect response” in an advanced mesothelioma patient.(PRWeb April 12, 2016)Read the full story at http://www.prweb.com/releases/2016/04/prweb13330247.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 12, 2016 Category: Pharmaceuticals Source Type: news
New Mesothelioma Immunogene Clinical Trial Set to Launch
For more than a decade, pulmonologist Dr. Dan Sterman has believed immunotherapy would become the catalyst for major advancements in the treatment of malignant pleural mesothelioma.
Today, he is closer than ever to proving that point.
Sterman, director of pulmonary medicine at New York University, soon will help launch a multicenter clinical trial involving a powerful immunogene therapy combination that may change the way this deadly asbestos-related cancer is viewed.
“I believe that immunotherapy will become the fourth pillar of treatment for mesothelioma (joining chemotherapy, radiation and surgery),” Sterma...
Source: Asbestos and Mesothelioma News - March 22, 2016 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news
New Mesothelioma Clinical Trial Hopes to Improve Chemotherapy
This study is part of a broad development program that includes a number of additional planned studies."
TRACON Pharmaceuticals develops novel targeted cancer therapies. Its TRC105 antibody is directed at renal cell carcinoma and hepatocellular carcinoma.
This clinical trial with TRC102 is one of five nationally involving methoxyamine, but one of more than 200 trials for mesothelioma. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - January 27, 2016 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news
Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
Dateline City:
INDIANAPOLIS and KENILWORTH, N.J.
INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s ALIMTA® (pemetrexed for injection) and Merck’s KEYTRUDA® (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the...
Source: Merck.com - Research and Development News - November 19, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
Lilly Says Court Ruled in its Favor on Patent
Eli Lilly & Co. said a federal court ruled that generic products proposed by a Teva Pharmaceutical Industries Ltd. unit would infringe a U.S. patent for the drug maker’s blockbuster cancer drug Alimta. (Source: WSJ.com: Health)
Source: WSJ.com: Health - August 25, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news
Eli Lilly wins UK Alimta drug patent case on appeal, shares jump
LONDON (Reuters) - Eli Lilly has won a patent case in the Court of Appeal in London over its blockbuster Alimta lung cancer drug, boosting prospects for future sales and dealing a blow to generic challenger Actavis, now renamed Allergan. (Source: Reuters: Health)
Source: Reuters: Health - June 25, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Bevacizumab May Be Next Standard of Care for Mesothelioma
Discussions About Mesothelioma at ASCO Meeting
There were other abstracts involving mesothelioma presented at the ASCO, adding even more optimism about potential treatment advances.
Dr. Raffit Hassan, mesothelioma specialist from the National Cancer Institute, detailed results of a phase I trial involving immunotherapy drug CRS-207 in combination with standard chemotherapy.
Disease control was obtained in 30 of the 32 trial participants. There was partial response in 19 patients and stable disease in 11. CRS-207 is given by
vaccination. Median duration of response was 5 months and median progression-fr...
Source: Asbestos and Mesothelioma News - June 5, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news
Collaborative group phase III study shows Roche’s Avastin improves survival in patients with mesothelioma - a devastating type of thoracic cancer
Roche announced today phase III results from a collaborative group study that showed that patients with malignant pleural mesothelioma, a rare type of cancer that affects the lining of the lungs, lived significantly longer when treated with Avastin in combination with standard therapy (pemetrexed and cisplatin chemotherapy) compared to standard therapy alone. (Source: Roche Investor Update)
Source: Roche Investor Update - May 30, 2015 Category: Pharmaceuticals Source Type: news
FDA Approves New Use for Immunotherapy Drug in Mesothelioma Treatment
The U.S. Food and Drug Administration (FDA) granted orphan drug designation last week to the immunotherapy vaccine CRS-207, moving it one step closer to changing the way malignant pleural mesothelioma is treated.
CRS-207 is derived from Listeria monocytogenes, a bacterium that causes the serious infection listeriosis. For the vaccine, the bacteria are weakened and genetically modified to produce an anti-tumor response without causing disease.
Early results are impressive.
The vaccine produced a 94 percent rate of disease control, either partial response or stable disease, according to a presentation made at the latest Inte...
Source: Asbestos and Mesothelioma News - April 7, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news
Eli Lilly loses Alimta drug patent case in Germany to Actavis
(Reuters) - Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine. (Source: Reuters: Health)
Source: Reuters: Health - March 6, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Merrimack begins Phase II trial of MM-121 to treat patients with heregulin positive NSCLC
US-based Merrimack Pharmaceuticals has started a Phase II clinical trial of its fully human monoclonal antibody, MM-121, in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone to treat patients with heregulin positive, local… (Source: Drug Development Technology)
Source: Drug Development Technology - February 20, 2015 Category: Pharmaceuticals Source Type: news
